



CCBIO

CAPTURING CANCER COMPLEXITY
AND CLINICAL CHALLENGES

CCBIO ANNUAL SYMPOSIUM

SCIENTIFIC PROGRAMS 2013 – 2023



Centre for
Cancer Biomarkers
Norwegian Centre of Excellence – University of Bergen



The Research Council of Norway



11th CCBIO ANNUAL SYMPOSIUM – MAY 8-10, 2023

Solstrand Hotel & Bad // Bergen // Norway

DAY 1: MONDAY MAY 8, 2023

10:00-11:30 REGISTRATION AND COFFEE

11:30-13:00 LUNCH

13:00-13:15 **Lars A. Akslen** (Director of CCBIO): Welcome and Opening

Session 1. Chair: Arne Östman

13:15-14:00 **Alexander Swarbrick** (Darlinghurst): Parsing breast cancer ecosystems with cellular genomics

14:00-14:45 **Ian Mills** (Oxford): Spatial lessons from prostate cancer research

14:45-15:30 COFFEE BREAK

Session 2. Chair: Line Bjørge

15:30-16:00 **Iain McNeish** (London): Ovarian cancer and copy number alterations

16:00-16:30 **Anniina Färkkilä** (Helsinki): How HRD/BRCA status influences the ovarian cancer TME

16:30-17:00 **Frédéric Amant** (Leuven/Amsterdam): How to organize translational cancer research, including the importance of preclinical models

19:30 DINNER

DAY 2: TUESDAY MAY 9, 2023

Session 3. Chair: Carina Strell

09:00-09:45 **Robert D'Amato** (Boston): Deciphering the mechanism of tumor acquired resistance to antiangiogenic therapies

09:45-10:15 **Michael Rogers** (Boston): What happens when an endothelial cell loses its compass? A role for CMG2 in chemotaxis

10:15-11:15 COFFEE BREAK

Session 4. Chairs: Katrin Kleinmanns and Line Bjørge

11:15-12:30 Speed presentations by young investigators

12:30-14:30 LUNCH AND POSTER SESSION I

Session 5. Chair: Anne Blanchard

14:30-15:45 Responsible clinical trials in the age of personalized medicine. Panel: **Linn Getz**, NTNU; **Caroline Engen**, Neuro-SysMed/UiB; **Line Bjørge** and **Karen Rosnes Gissum**, CCBIO.

15:45-16:15 COFFEE BREAK

Session 6. Chair: Agnete Engelsen

16:15-16:45 **Stephane Terry** (Paris): Role of hypoxia, EMT and AXL in cancer immune escape

16:45-17:15 **Ingrid Hedenfalk** (Lund): Exploring the normal-like subtype of breast cancer

19:30 DINNER

DAY 3: WEDNESDAY MAY 10, 2023

Session 7. Chair: Karl-Henning Kalland

09:00-09:45 **Klaus Pantel** (Hamburg): Liquid biopsy: From discovery to clinical implementation

09:45-10:15 **Catherine Alix-Panabières** (Montpellier): Metastasis-initiator circulating tumor cells in colon and breast cancers

10:15-10:45 COFFEE BREAK

Session 8. Chair: Jim Lorens

10:45-11:15 **Mark LaBarge** (Duarte, CA): Integrating noise into a signal: loss of lineage specificity presages breast cancer susceptibility

11:15-11:45 **Amy LeBlanc** (Bethesda, MD): The US National Cancer Institute's Comparative Oncology Program: Contributions to cancer research and drug development

11:45-12:15 **Benno Schwikowski** (Paris): How to build computational approaches to discover causal paths in cancer

12:15-12:45 **Rameen Beroukhim** (Boston): Detecting effects of SVs on cancer cellular fitness

12:45-14:45 LUNCH AND POSTER SESSION II

Session 9. Chair: Bjørn Tore Gjertsen

14:45-15:15 **Caroline Heckman** (Helsinki): Functional precision medicine for treatment and biomarker discovery in high-risk hematological malignancies

15:15-15:45 **Brunangelo Falini** (Perugia): Impact of anti-NPM1 monoclonal antibodies in the characterization of NPM1-mutated AML

15:45-16:30 **Jean Paul Thiery** (Singapore): Development of differentiation and immunotherapy strategies interfering with bladder carcinoma progression

16:30-16:45 **Line Bjørge** (Co-Director of CCBIO): Closing remarks



10th CCBIO ANNUAL SYMPOSIUM – MAY 10-11, 2022

Solstrand Hotel & Bad // Bergen // Norway + online

DAY 1: TUESDAY MAY 10, 2022

09:00-09:45 REGISTRATION AND COFFEE

09:45-10:00 **Lars A. Akslen** (Director of CCBIO): Welcome and Opening

Session 1. Chair: Bjørn Tore Gjertsen

10:00-11:00 **Robert S. Langer** (Cambridge, MA): From a 1976 Nature paper to a 2020 mRNA vaccine: How overcoming scepticism and barriers led to new cancer treatments and the solution to a global health challenge

11:00-11:30 **Olli Kallioniemi** (Stockholm): Functional and data-driven precision medicine in acute myeloid leukemia

11:30-12:00 **Malin Sund** (Umeå): Early detection of pancreatic cancer

12:00-12:30 **Daniel Öhlund** (Umeå): Targeting tumor-stromal interactions in pancreatic cancer

12:30-14:30 LUNCH AND POSTER SESSION I

Session 2. Chair: Roger Strand

14:30-15:45 Imaginaries of precision oncology. Panel: **Marta Bertolaso** (Roma), **Anne Blanchard** (Bergen), **Dominique Chu** (Canterbury) and **Bjørn Hofmann** (Gjøvik, Oslo)

15:45-16:30 COFFEE BREAK

Session 3. Chair: Oddbjørn Straume

16:30-17:00 **Carina Strell** (Uppsala/Stockholm): Tumor-stroma interactions driving the progression and therapyresistance of DCIS

17:00-17:30 **Christine Desmedt** (Leuven): Unraveling disease progression and treatment resistance in patients with lobular breast cancer

19:30 DINNER



DAY 2: WEDNESDAY MAY 11, 2022

Session 4

09:00-09:45 **Gooitzen van Dam** (Groningen): Clinical molecular imaging: a multidisciplinary tool in cancer treatment from drug development, image-guided surgery to cancer pathology

09:45-10:15 **Sébastien Wälchli** (Oslo): From classic to modern CAR repertoire

10:15-10:45 COFFEE BREAK

Session 5. Chair: Jim Lorens

10:45-11:15 **Srinivas Malladi** (Dallas): Uncovering targetable vulnerabilities of breast cancer brain metastatic cells

11:15-11:45 **Rolf Brekken** (Dallas): Restoring sensitivity to immune checkpoint blockade through inhibition of AXL

11:45-14:00 LUNCH AND POSTER SESSION II

Session 6. Chairs: Liv C. V. Thomsen and Line Bjørge

14:00-15:15 Speed presentations by young investigators

Session 7. Chair: Dana Costea

15:15-15:45 **Matthias Nees** (Turku): Automated tracking of tumor-stroma morphology in microtissues identifies targets within the tumor microenvironment for therapeutic intervention

14:45-16:15 **Silvio Gutkind** (La Jolla, CA, digitally): Targeting the PIK3CA-mTOR network in head and neck cancer: New multimodal precision immunotherapies

16:15-16:30 **Roger Strand** (CCBIO PI): Closing remarks



9th CCBIO ANNUAL SYMPOSIUM – MAY 19-20, 2021

Virtual event in Zoom

(The 8th Symposium in 2020 was cancelled due to the pandemic)

DAY 1: WEDNESDAY MAY 19, 2021

10:00-10:15 **Lars A. Akslen** (Director of CCBIO): Welcome and opening

Session 1. Chairs: Karl-Henning Kalland and Oddbjørn Straume

11:00-11:45 **Klaus Pantel** (Hamburg): Liquid Biopsy: From discovery to clinical implementation

11:45-12:15 **Ulf Landegren** (Uppsala): Molecular tools for biomarker analysis in immune oncology

12:15-12:45 **Lewis Au** (London): Determinants of anti-PD1 response and resistance in renal cell carcinoma

12:45-13:00 Questions and Discussion

13:00-14:00 BREAK

Session 2. Chairs: Camilla Krakstad and Liv Cecilie Vestrheim Thomsen

14:00-15:00 Speed presentations by young investigators (replacing posters)

15:00-16:00 BREAK

Session 3. Chairs: Jim Lorens and Rolf Brekken

16:00-16:45 **Bernd Bodenmiller** (Zürich): Highly multiplexed imaging of tissues with subcellular resolution by imaging mass cytometry

16:45-17:15 **Morag Park** (Montreal): Tumor zonation and immune microenvironments in triple negative breast cancer

17:15-17:45 **Ezra Cohen** (San Diego, CA): Neoantigen identification and use as biomarkers

17:45-18:15 **Genevieve Boland** (Boston): Multi-modality approach to predicting and monitoring immunotherapy response and resistance

18:15-18:30 Questions and Discussion



DAY 2: THURSDAY MAY 20, 2021

Session 4. Chairs: Daniela Costea and Agnete Engelsen

11:00-11:50 **Hans Clevers** (Utrecht): Organoids to model human diseases

11:50-12:10 **Daniela Costea** (Bergen): 3D organotypic models of human squamous cell carcinoma

12:10-12:40 **Amir Aref** (Boston): Patient derived organoids in cancer research

12:40-13:00 Questions and Discussion

13:00-14:00 BREAK

Session 5. Chairs: Elisabeth Wik and Cornelia Schuster

14:00-15:00 Speed presentations by young investigators (replacing posters)

15:00-16:00 BREAK

Session 6. Chairs: Line Bjørge and Bjørn Tore Gjertsen

16:00-16:30 **Anil Sood** (Houston): Ovarian cancer – understanding the mechanisms of adaptive resistance to anti-angiogenesis drugs

16:30-17:00 **Jeffrey Pollard** (Edinburgh): Monocyte regulation in homeostasis and malignancy

17:00-17:30 **Kara Davis** (Palo Alto, CA): Understanding childhood leukemia through the lens of normal development: Single-cell studies for clinical translation

17:30-18:00 **Hani Gabra** (London): Regulation of receptor tyrosine kinases by OPCML – biology and potential therapies

18:00-18:15 Questions and Discussion

18:15-18:30 **Bjørn Tore Gjertsen** (Co-Director of CCBIO): Closing remarks



7th CCBIO ANNUAL SYMPOSIUM – MAY 13-14, 2019

Solstrand Hotel & Bad // Bergen // Norway

DAY 1: MONDAY MAY 13, 2019

09:00-10:00 REGISTRATION AND COFFEE

10:00-10:15 **Lars A. Akslen** (Director of CCBIO): Introduction to the CCBIO Symposium 2019

Chair: Bjørn Tore Gjertsen

10:15-11:00 **Bob Löwenberg** (Rotterdam): Directions in the treatment of acute myeloid leukemia

11:00-11:45 **William D. Foulkes** (Montreal): How do we identify those at risk for hereditary cancer?

11:45-12:30 **Vicky Seewaldt** (South Pasadena, CA): Systems biology approach to improve survival of Black and Latina women with biologically aggressive breast cancer

12:30-14:30 LUNCH AND POSTER SESSION I

Chair: Mark LaBarge

14:30-15:15 **Jonathan Irish** (Nashville): Hacking the signals that control cell identity using single cell mass cytometry

15:15-15:45 **Nick Tobin** (Stockholm): Assessing the clinical relevance of gene expression signatures in primary and metastatic breast cancer

15:45-16:15 **Xisong Ke** (Bergen): Discovery and target identification of anti-cancer drugs

16:15-16:45 COFFEE BREAK

Chair: Roger Strand

16:45-17:45 **Eirik Tranvåg & Roger Strand** (Bergen): Which patient to treat? An interactive priority setting survey

19:30 DINNER



DAY 2: TUESDAY MAY 14, 2019

Chair: Jean Paul Thiery

09:00-09:30 **Marco Davila** (Tampa, FL): Improving the safety and efficacy of CAR-T cell therapies

09:30-10:00 **Randy Watnick** (Boston): Development of a therapeutic peptide that reprograms the tumor immune microenvironment

10:00-10:30 **Duanqing Pei** (Zhejiang): New strategies and molecular insight in cellular reprogramming

10:30-11:00 COFFEE BREAK

Chair: Ian Mills

11:00-11:30 **Eric B. Haura** (Tampa, FL): Visualizing protein complexes as molecular diagnostics

11:30-12:00 **Agnete Engelsen** (Bergen): Microenvironment-induced Axl signaling is required for epithelial phenotypic plasticity

12:00-12:30 **Alea Mills** (New York): Strengths & vulnerabilities of human glioma

12:30-13:00 **Caroline Heckman** (Helsinki): Bone marrow stroma derived factors and other mechanisms of resistance to therapy in hematological malignancies

13:00-14:45 LUNCH AND POSTER SESSION II

Philosophy of Cancer. Chair: Roger Strand

14:45-15:15 **Marta Bertolaso** (Rome): Models and explanations in cancer research

Translation & Innovation. Chair: Yves Aubert

15:15-15:30 **Yves Aubert** (Bergen): Creating impact through innovation

15:30-16:30 Volterra Lecture by **Omid Farokhzad** (Bergen): Perspectives on how to translate biomedical research to products and cures (*This keynote address is part of the distinguished Volterra Lectures series organized by Digital Life Norway (DLN). The session is sponsored by CCBIO, Digital Life Norway, VIS, and The Faculty of Medicine, UIB*)

16:30-16:45 **Roger Strand** (CCBIO PI): Closing remarks



6th CCBIO ANNUAL SYMPOSIUM – MAY 23-24, 2018

Solstrand Hotel & Bad // Bergen // Norway

DAY 1: WEDNESDAY MAY 23, 2018

09:00-10:00 REGISTRATION AND COFFEE

10:00-10:15 **Lars A. Akslen** (Director of CCBIO): Introduction to the CCBIO Symposium 2018

Chair: Randy Watnick

10:15-11:00 **Richard O. Hynes** (Cambridge): Extracellular matrix vulnerabilities in cancer

11:00-11:30 **Bruce Zetter** (Boston): RNA therapy in the treatment of cancer

11:30-12:00 **Frederick Locke** (Tampa): CAR T-cell technology against cancer

12:00-12:30 **Thomas F. Meyer** (Berlin): Do bacterial pathogens provoke distinct mutations in their host?

12:30-14:30 LUNCH AND POSTER SESSION I

Chair: Arne Östman

14:30-15:00 **Therese Sørli** (Oslo): Mouse models for breast cancer progression

15:00-15:30 **Carina Strell** (Uppsala/Stockholm): Exploring stroma characteristics as mediators of breast DCIS progression and as markers for radiation-response

15:30-16:00 **Ian G. Mills** (Oxford/Belfast): Stress response signalling in prostate cancer

16:00-16:30 COFFEE BREAK

Chair: Roger Strand

16:30-17:15 **Leonard Fleck** (East Lansing, MI): Just caring challenges: Visible biomarkers and invisible rationing

17:15-17:45 Comment I: **Oddbjørn Straume**

Comment II: **Ole Frithjof Norheim**

19:30 DINNER



DAY 2: THURSDAY MAY 24, 2018

Chair: Rolf Brekken

09:00-09:30 **Sui Huang** (Chicago, IL): Non-genetic heterogeneity and non-linear dynamics of tumors: Why cancer treatment can backfire

09:30-10:00 **Mark LaBarge** (Dartmouth, CA): The role of microenvironment in cancer susceptibility and drug tolerance

10:00-10:30 **Ole W. Petersen** (Copenhagen): On the candidate cells of origin of human breast cancer

10:30-11:00 COFFEE BREAK

Chair: Dana Costea

11:00-11:20 **Fanny A. Vatter** (New York): High-dimensional analysis of single human mammary epithelial cells with age

11:20-11:40 **Kenneth Finne** (Bergen): Proteomic profiles across breast cancer subtypes

11:40-12:00 **Gry S. Haaland** (Bergen): Association of warfarin use with lower overall cancer incidence

12:00-12:20 **Liv C. V. Thomsen** (Bergen): Cryoimmunotherapy against cancer – status and outlook

12:20-14:20 LUNCH AND POSTER SESSION II

Chair: Karl-Henning Kalland

14:20-14:50 **William N. William Jr.** (São Paulo/Houston): Developing personalized cancer prevention and therapy strategies: a clinical trials perspective

14:50-15:20 **Christina Fotopoulou** (London): Predictive biomarkers in the surgical treatment of epithelial ovarian cancer

15:20-15:50 **Ursula Klingmueller** (Heidelberg): From insights into regulation of erythropoiesis towards optimized treatment of anemia

15:50-16:20 **Hrvoje Miletic** (Bergen): Microtubes – communication structures of brain tumor cells

16:20-16:30 **Bjørn Tore Gjertsen** (Co-Director of CCBIO): Closing remarks



5th CCBIO ANNUAL SYMPOSIUM – APRIL 19-20, 2017

Solstrand Hotel & Bad // Bergen // Norway

DAY 1: WEDNESDAY APRIL 19, 2017

09:00-10:00 REGISTRATION AND COFFEE

10:00-10:15 **Lars A. Akslen** (Director of CCBIO): Introduction to the CCBIO Symposium 2017

Chair: Jean Paul Thiery

10:15-11:00 **John Heymach** (Houston): EMT, immunomodulation and therapeutic resistance

11:00-11:45 **Angela Nieto** (San Juan de Alicante): The partial EMT and cell plasticity in fibrosis and cancer

11:45-12:30 **Robert Gale** (London / Los Angeles): What precisely is precision oncology and will it work?

12:30-14:30 LUNCH AND POSTER SESSION I

Young investigators. Chair: Bjørn Tore Gjertsen

14:30-14:50 **Erling A. Høivik** (Bergen): The genetic evolution of endometrial cancer metastasis

14:50-15:10 **Randi Hovland** (Bergen): Liquid biopsy biomarkers in clinical trials

15:10-15:30 **Oddmund Nordgård** (Stavanger): Liquid biopsies in pancreatic cancer

15:30-15:50 **Thomas Arnesen** (Bergen): N-terminal acetyl-transferases - novel cancer drug targets

15:50-16:10 **Eirik Tranvåg** (Bergen): Biomarkers and potential impact on priority setting

16:10-16:40 COFFEE BREAK

16:40-16:50 **Roger Strand** (Bergen): Book Presentation: "Cancer Biomarkers: Ethics, Economics, and Society"

Chair: Oddbjørn Straume

16:50-17:20 **Diane Bielenberg** (Boston): Expression of neuropilins in the epithelium and endothelium are biomarkers of cancer progression

17:20-17:50 **Kristin Taskén** (Oslo): What's up with adrenergic receptor signaling and prostate cancer?

19:30 DINNER



DAY 2: THURSDAY APRIL 20, 2017

Chair: Donald Gullberg

09:00-09:45 **Carl Henrik Heldin** (Uppsala): Signaling via TGF β receptors: possible targets in tumor treatment

09:45-10:15 **Jean-Christophe Bourdon** (Dundee): The cell response to anticancer drugs is defined by the p53 protein isoforms in mutant TP53 cells

10:15-10:45 **Krister Wennerberg** (Copenhagen): Systems medicine methods for identification of stratified leukemia therapies and their predictive biomarkers

10:45-11:15 COFFEE BREAK

Chair: Karl-Henning Kalland

11:15-11:45 **Salem Chouaib** (Paris): Effect of hypoxic stress on the cytotoxic anti-tumor response

11:45-12:15 **Spiros Kotopoulos** (Bergen): Targeting cells with ultrasound: from theory to reality

12:15-14:15 LUNCH AND POSTER SESSION II


Chair: Emmet McCormack

14:15-14:45 **Frédéric Amant** (Leuven): Patient derived xenografts as a preclinical model

14:45-15:15 **Janine Terra Erler** (Copenhagen): ECM remodelling during cancer progression

15:15-15:45 **Jeanette Wood**: Role of pharma, biotech, academia and funding bodies in drug discovery innovation

15:45-16:00 **Bjørn Tore Gjertsen** (Co-Director of CCBIO): Closing remarks



4th CCBIO ANNUAL SYMPOSIUM – MAY 10-11, 2016

Solstrand Hotel & Bad // Bergen // Norway

DAY 1: TUESDAY MAY 10, 2016

09:00-10:00 REGISTRATION AND COFFEE

10:00-10:15 **Lars A. Akslen** (Director of CCBIO): Introduction to the CCBIO Symposium 2016

Chair: Lars A. Akslen

10:15-11:00 **Marsha A. Moses** (Boston): Mining the human proteome: Biomarker discovery for human cancer and its metastases

11:00-11:45 **Meenhard Herlyn** (Philadelphia): Tumor microenvironment and drug resistance

11:45-12:30 **Brunangelo Falini** (Perugia): NPM1-mutated acute myeloid leukemia: biological and clinical features

12:30-14:30 LUNCH AND POSTER SESSION I

Young investigators. Chair: Randy Watnick

14:30-14:50 **Elisabeth Wik** (Bergen): An angio-immunogenic profile of basal-like breast cancer; relevance of cancer testis antigens

14:50-15:10 **Siver Moestue** (Trondheim): Imaging-based biomarkers in breast cancer

15:10-15:30 **Guro Lind** (Oslo): Identifying and developing DNA methylation cancer biomarkers for clinical use

15:30-15:50 **Kelly Seo** (London): Impact of cancer biomarkers on the cost-effectiveness of targeted therapies, focusing on mCRC/metastatic colorectal cancer

15:50-16:45 COFFEE BREAK

Chair: Donald Gullberg

16:45-17:15 **Ritva Heljasvaara** (Oulu): Collagen XVIII in breast cancer - a regulator of growth factor receptor-integrin crosstalk and a therapeutic target

17:15-17:45 **Anne Blanchard** (Bergen): Cancer biomarkers looking for patients

19:00 DINNER

DAY 2: WEDNESDAY MAY 11, 2016

Chair: Jim Lorens

09:00-09:30 **Karl Johan Malmberg** (Oslo): Allogeneic natural killer cell therapy against high-risk myeloid dysplastic syndrome

09:30-10:00 **Rolf Brekken** (Dallas): Phosphatidylserine signaling and immune suppression in the tumor microenvironment

10:00-10:30 **Salem Chouaib** (Paris): Hypoxia and the anti-tumor response

10:30-11:00 **Michael Curran** (Houston): Hypoxia is an essential driver of immune suppression in the tumor microenvironment

11:00-11:30 COFFEE BREAK

Chair: Oddbjørn Straume

11:30-12:15 **Thorsten Schlomm** (Hamburg): Diversity of prostate cancer: Implication for translational research

12:15-12:45 **Hani Gabra** (London): OPCML, a negative regulator of receptor Tyrosine kinases in ovarian cancer: new biology, new therapy?

12:45-14:30 LUNCH AND POSTER SESSION II

Young investigators. Chair: Bjørn Tore Gjertsen

14:30-14:50 **Emmet McCormack** (Bergen): Avatars and imaging in cancer therapy development

14:50-15:10 **Camilla Krakstad** (Bergen): Exploring biomarkers for endometrial cancer

15:10-15:30 **Dana Costea** (Bergen): Effects of nanodiamond modified copolymer scaffolds on tumor progression

15:30-15:50 **Ingfrid Haldorsen** (Bergen): Imaging biomarkers relevant for angiogenesis in endometrial cancer

15:50-16:05 **Xisong Ke** (Bergen): Cancer therapy: Identification of novel targets

16:05-16:15 **Bjørn Tore Gjertsen** (Co-Director of CCBIO): Closing remarks



3rd CCBIO ANNUAL SYMPOSIUM – MAY 19-20, 2015

Solstrand Hotel & Bad // Bergen // Norway

DAY 1: TUESDAY MAY 19, 2015

09:00-10:00 REGISTRATION AND COFFEE

10:00-10:15 **Lars A. Akslen** (Director of CCBIO): Introduction to the CCBIO Symposium 2015

Chair: James Lorens

10:15-11:00 **Jean Paul Thiery** (Singapore): Epithelial-mesenchymal transition (EMT)-based therapeutic strategies in cancer

11:00-11:45 **Thomas Brabletz** (Erlangen): Cellular plasticity in cancer: driving force and therapeutic target

11:45-12:15 **Randolph Watnick** (Boston): The role of Notch1 and p53 in modulating the cancer stem cell phenotype

12:15-14:15 LUNCH AND POSTER SESSION I

Chair: Roger Strand

14:15-14:45 **John Cairns** (London): Challenges in valuing the benefits of new cancer therapies

14:45-15:15 **Ole Frithjof Norheim** (Bergen): Valuing the benefits of new therapies: recommendations from the third national committee on priority setting in Norway

15:15-15:45 **Roger Strand** (Bergen): Sociotechnical imaginaries of cancer biomarkers - a preliminary analysis

15:45-16:15 COFFEE BREAK

Chair: Rolf Reed

16:15-16:45 **Thorarinn Gudjonsson** (Reykjavik): Cellular processes during breast morphogenesis and EMT: an approach from 3D culture

16:45-17:15 **James Lorens** (Bergen): Multipotent mammary stem cell activity requires Axl receptor tyrosine kinase

17:15-17:45 **Karl-Henning Kalland** (Bergen): Prostate cancer - new therapeutic approaches

19:00 DINNER



DAY 2: WEDNESDAY MAY 20, 2015

Chair: Arne Östman

09:00-09:45 **David Tuveson** (New York): Pancreatic cancer models and medicine

09:45-10:15 **Arne Östman** (Stockholm): Cancer-associated fibroblasts and pericytes as sources of prognostic and predictive information

10:15-10:45 **Per Ø. Enger** (Bergen): Brain tumor stroma interactions from a translational perspective

10:45-11:15 COFFEE BREAK

Chair: Helga Salvesen

11:15-12:00 **Ravi Bhatia** (Birmingham, AL): Targeting leukemia stem cells in myeloid malignancies

12:00-12:30 **Bjørn Tore Gjertsen** (Bergen): Biomarkers in individualized cancer trials – hype or future cancer care?

12:30-14:15 LUNCH AND POSTER SESSION II

Chair: Karl-Henning Kalland

14:15-15:00 **Klaus Pantel** (Hamburg): Liquid biopsy: Implications for cancer therapy

15:00-15:30 **Odd Helge Gilja** (Bergen): Ultrasound sonoporation applied experimentally and in patients with pancreatic adenocarcinoma

15:30-16:00 **Guttorm Haraldsen** (Oslo): Interleukin-33 - an important factor in stromal inflammation

16:00-16:30 **Nils Halberg** (Bergen): A microRNA regulon that mediates breast cancer metastasis

16:30-16:45 **Lars A. Akslen** (Bergen): Closing remarks



2nd CCBIO ANNUAL SYMPOSIUM – MARCH 25-26, 2014

Solstrand Hotel & Bad // Bergen // Norway

DAY 1: TUESDAY MARCH 25, 2014

09:00-10:00 REGISTRATION AND COFFEE

10:00-10:15 **Lars A. Akslen** (Director of CCBIO): Introduction to the CCBIO Symposium 2014

Chair: James Lorens

10:15-11:00 **Rameen Beroukhim** (Boston): Interpreting cancer copy-number alterations

11:00-11:30 **Helga Salvesen** (Bergen): Molecular profiling of primary compared to metastatic lesions in gynecologic cancers

11:30-12:00 **Therese Sørli** (Oslo): Gene expression patterns and biomarkers in subtypes of breast cancer

12:00-14:00 LUNCH AND POSTER SESSION I

Chair: Donald Gullberg

14:00-14:45 **Mark LaBarge** (San Francisco): Insights into aging and cancer through deconstruction and recapitulation of human mammary microenvironments in culture

14:45-15:15 **James Lorens** (Bergen): The role of the Axl receptor tyrosine kinase in drug resistance and metastasis

15:15-15:45 COFFEE BREAK

15:45-16:15 **Ian Mills** (Oslo): An interplay between transcription and metabolic reprogramming in prostate cancer

16:15-16:45 **Karl-Henning Kalland** (Bergen): Cancer cell heterogeneity and reprogramming plasticity – therapeutic possibilities

19:00 DINNER



DAY 2: WEDNESDAY MARCH 26, 2014

Chair: Helga B. Salvesen

09:00-09:45 **Valerie Weaver** (San Francisco): Tissue tension reprograms the tissue to metastasis

09:45-10:15 **Donald Gullberg** (Bergen): Fibroblast integrins in wounds, scars and tumors – emerging molecular themes

10:15-10:45 **Randolph Watnick** (Boston): Development of a novel multimodal therapeutic agent targeting the tumor microenvironment

10:45-11:15 COFFEE BREAK

11:15-12:00 **Johanna Ivaska** (Turku): Cell-matrix interactions in cancer

12:00-12:45 **Taina Pihlajaniemi** (Oulu): Multiplexin collagens in development and maintenance of tissue homeostasis and in malignant growth

12:45-14:15 LUNCH AND POSTER SESSION II


Chair: Karl-Henning Kalland

14:15-14:45 **Bruce Zetter** (Boston): New approaches to metastatic cancer

14:45-15:15 **Kjetil Taskén** (Oslo): Regulation of anti-tumor immune responses in colorectal cancer

15:15-15:45 **Bjørn Tore Gjertsen** (Bergen): Personalized medicine and clonal evolution in acute leukemia?

15:45-16:00 **Lars A. Akslen** (Bergen): Closing remarks



OPENING SYMPOSIUM – MAY 30-31, 2013

Store auditorium // Haukeland University Hospital // Bergen // Norway

DAY 1: THURSDAY MAY 30, 2013

12:30-13:00 REGISTRATION, COFFEE AND LIGHT FOOD

Session 1, Welcome and official opening. Chair: Dean Nina Langeland

13:00-13:30 Welcoming announcement and short presentation of the Centre for Cancer Biomarkers by CCBIO's Director, **Lars A. Akslen** (University of Bergen)

13:30-14:30 Official opening, short speeches and congratulatory statements

14:30-15:00 COFFEE AND LIGHT FOOD

Session 2, Biomarkers: Tradition and Future. Chair: Rolf Reed

15:00-15:45 Keynote lecture I: **Bruce Zetter** (Harvard Medical School): New mechanisms and biomarkers of chemoresistance

15:45-16:30 Keynote lecture II: **Mina Bissell** (Lawrence Berkeley National Laboratory): Engineered models of dormancy and metastasis: the importance of the extracellular matrix

DAY 2: FRIDAY MAY 31, 2013

Session 3, Biomarkers: Ethical, legal and economic aspects. Chair: Oddvar Kaarbøe

10:00-10:30 Keynote lecture III: **John Cairns** (London School of Hygiene & Tropical Medicine): The economic evaluation of cancer biomarkers

10:30-11:30 **Roger Strand** (University of Bergen): From ethics to ELSA of research on cancer biomarkers
Oddvar Martin Kaarbøe (University of Bergen): Economic aspects of biomarkers
Comments by **Ole Frithjof Nordheim** (University of Bergen)

11:30-13:00 LUNCH & POSTER SESSION, ASSEMBLY HALL, BBB

Session 4, Biomarkers: From basic to clinical studies. Chair: Bjørn Tore Gjertsen

13:00-15:00 **Arne Östman** (Karolinska Institute): PDGF-dependent CAFs and pericytes; impact on metastasis and prognosis

Christopher Hughes (University of California Irvine): Angiogenesis and the tumor microenvironment

Randolph Watnick (Harvard Medical School): Development of a novel therapeutic peptide for the treatment of advanced cancer

Rolf Brekken (University of Texas): Macrophages and metastasis: targeting prometastatic macrophages and the products they make

Ate van der Zee (University of Groningen): Examples of biomarker research in gynaecologic oncology

15:00-15:30 COFFEE BREAK

15:30-17:30 **George N. Naumov** (Merck Research Laboratories Boston): Development and biomarker strategy of novel combination therapies using two investigational oncology agents

Oddbjørn Straume (University of Bergen): Angiogenesis as a treatment target in metastatic melanoma

Biaoyang Lin (University of Washington): Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach

James Lorens (University of Bergen): Stem cells, EMT and cancer: The role of the Axl receptor

17:30-17:35 **Lars A. Akslen**: Summing up and closing

